Korea vs Western Pacific (WHO region): Previously treated cases tested for RR-/MDR-TB
Korea
100.0%
in 2024
Western Pacific (WHO region)
86.0%
in 2024
Korea rank
1st
Western Pacific (WHO region) rank
3rd
Previously treated cases tested for RR-/MDR-TB over time
- Korea
- Western Pacific (WHO region)
How they compare
Korea currently reports 100.0% against 86.0% in Western Pacific (WHO region), a difference of 14.0%.
That makes Korea's figure about 1.2 times Western Pacific (WHO region)'s.
The two have swapped places 2 times across 13 shared years of data; in 2011 it was Korea ahead.
Korea ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
Across the 2 decades both report, Korea averaged higher in 1 and Western Pacific (WHO region) in 1.
Head to head by decade
| Decade | Korea | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 55.5% | 66.9% | 11.4% | Western Pacific (WHO region) |
| 2020s | 92.0% | 89.2% | 2.8% | Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Korea or Western Pacific (WHO region)?
- Korea, at 100.0% against 86.0% in Western Pacific (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Korea and Western Pacific (WHO region)?
- 14.0%, with Korea ahead.
- How many years of comparable data are there for Korea and Western Pacific (WHO region)?
- 13 years are reported by both, from 2011 to 2024.
- How do Korea and Western Pacific (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Korea ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.